Treatment with exenatide in acute ischemic stroke trial protocol: A prospective, randomized, open label, blinded end-point study of exenatide vs. standard care in post stroke hyperglycemia

What Was Tested

The paper reports a study of Exenatide, published as a randomized controlled trial.

Design TEXAIS is a three year, Phase 2, multi-center, prospective, randomized, open label, blinded end-point trial comparing exenatide to standard of care.

Secondary outcomes of hyper- and hypoglycaemia at 5 days and NIHSS and mRS at 90 days will be measured.

Who Took Part

According to the abstract, 528 patients were involved.

The age groups tagged for this paper are teenagers, young adults, adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a randomized and open-label study.

Random assignment meant chance, not the researchers, decided who got Exenatide and who got the comparison, which limits bias.

Nothing was hidden in this open-label Exenatide study: the patients and staff both knew the treatment.

What Was Measured

Secondary outcomes of hyper- and hypoglycaemia at 5 days and NIHSS and mRS at 90 days will be measured.

Topics PubMed links to this paper include Brain Ischemia, Exenatide, Hyperglycemia, Hypoglycemic Agents and Stroke.

Author keywords: Acute stroke therapy, glucagon-like peptide-1 analog, incretin, ischemic stroke and neuroprotection.

What This Means in Plain Language

The paper is a randomized and open-label study of Exenatide in 528 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

The publication is from 2018 (International journal of stroke : official journal of the International Stroke Society), a journal based in United States.

More context: the Exenatide compound page, all human trials.